Glioblastoma remains a highly challenging malignancy with a pronounced tendency for recurrence. The hypoxic microenvironment ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A Virginia-based biotech company has announced dosing of ...
NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening rare diseases by harnessing the power of the immune ...
Results of a VHIO led study show that up to 90% of chronically hypoxic patients have an EPAS1 alteration in their tumor, a gene critical for adapting to lack of oxygen in populations living at ...
Synaptic injury in the IPL of the retina is linked to MS progression, with IPL thickness as a potential biomarker. Hypoxia in MS patients exacerbates inflammation and mitochondrial damage, ...
ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results